PRODUCT INFORMATION



UR-144 N-pentanoic acid metabolite-d₅

Item No. 14376

CAS Registry No.: 2117405-23-7

Formal Name: 5-(3-(2,2,3,3-tetramethyl-

cyclopropanecarbonyl)-1H-indol-1-yl-

2,4,5,6,7-d₅)pentanoic acid

Synonym: XLR11 N-pentanoic acid metabolite-d_E

MF: $C_{21}H_{22}D_5NO_3$

FW: 346.5

Chemical Purity: ≥98% (UR-144 N-pentanoic acid metabolite)


Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₅); \leq 1% d₀

UV/Vis.: λ_{max} : 217, 246, 303 nm Supplied as: A crystalline solid

-20°C Storage: Stability: ≥5 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Description

UR-144 N-pentanoic acid metabolite-d₅ (Item No. 14376) is intended for use as an internal standard for the quantification of UR-144 N-pentanoic acid metabolite (Item No. 11773) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

UR-144 (Item No. 11502) is a potent synthetic cannabinoid (CB) that preferentially binds the peripheral CB_2 receptor (K_i = 1.8 nM) over the central CB_1 receptor (K_i = 150 nM). UR-144 N-pentanoic acid metabolite is an expected phase I metabolite of UR-144, based on the metabolism of similar cannabimimetics. 2.3 This metabolite should be detectable in either serum or urine.^{2,3} The physiological and toxicological properties of this compound have not been tested. This product is intended for forensic and research applications.

References

- 1. Frost, J.M., Dart, M.J., Tietje, K.R., et al. Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB₂ cannabinoid receptor activity. J. Med. Chem. 53(1), 295-315 (2010).
- Wintermeyer, A., Möller, I., Thevis, M., et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 398(5), 2141-2153 (2010).
- 3. Chimalakonda, K.C., Moran, C.L., Kennedy, P.D., et al. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal. Chem. 83(16), 6381-6388 (2011).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 06/16/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM